Clinical Trial Update: Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Vidaza (azacitidine) and valproic acid after allogeneic transplant in high-risk AML and MDS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• VALPROIC ACID (Valproic acid)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Patrick Stiff | Conditions: Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS | Phase 2 | Status: UNKNOWN